

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

ESTIMATED RESULTS FOR THE HALF YEAR ENDED 30 JUNE 2023

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”, and together with its subsidiaries, the “Group”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

Pursuant to Rule 5.1.1 of the *Listing Rules of the Shanghai Stock Exchange* (《上海证券交易所股票上市规则》) (2023 Revision) (the “SSE Listing Rules”), where the net profit of a listed company for the half year is estimated to increase or decrease more than 50% compared to that for the same period in the previous year, such listed company is required to release an announcement on the estimated results for the half year within 15 days after the end of the half year.

The Company wishes to inform the shareholders and potential investors of the Company that, the net profit attributable to the owners of the parent for the half year ended 30 June 2023 (“1H2023”) is estimated to increase more than 50% compared to that for the half year ended 30 June 2022 (“1H2022”) and accordingly, the Company is making this announcement in accordance with the SSE Listing Rules and Rules 217 and 703 of the Listing Manual of the Singapore Exchange Securities Trading Limited. Further details are set out below.

1. Estimated results for 1H2023

(a) Period of the estimated results

1 January 2023 to 30 June 2023.

(b) Estimated results

Based on a preliminary assessment by the finance department of the Company:

- (i) the net profit attributable to the owners of the parent for 1H2023 is estimated to range from approximately RMB703 million to RMB750 million, an increase of between approximately RMB234,214,900 to RMB281,214,900 as compared to that for 1H2022, representing a year-on-year increase of between approximately 50% and 60%.
- (ii) the net profit attributable to the owners of the parent after deducting non-recurring gain or loss for 1H2023 is estimated to range from approximately RMB697 million to RMB744 million, an increase of between approximately RMB232,753,300 to RMB279,753,300 as compared to that for 1H2022, representing a year-on-year increase of between approximately 50% and 60%.

(c) The estimated results set out above have not been audited by any accounting firm.

2. Operation results for 1H2022

(a) The net profit attributable to the owners of the parent for 1H2022 was RMB468,785,100 and the net profit attributable to the owners of the parent after deducting non-recurring gain or loss for 1H2022 was RMB464,246,700.

(b) The earnings per ordinary share for 1H2022 was RMB0.61 per share.

3. Reasons for the increase in results

Focusing on the "14th Five-Year" development plan, the Company seized market opportunities, further carried forward the "One plus Five" strategy and implemented the strategic plan of "Three Cores and Nine Wings (三核九翼)" using brand as the leading point, enhanced strengths of the Company's advantageous product varieties, as well as carried out various measures including brand strengthening, market expansion, costs reduction, and resources integration, and thus achieved a steady increase in sales revenue and gross profit of the products in the industrial sectors in 1H2023. In addition, the operating performance of the associates invested by the Company also increased significantly in 1H2023.

4. Risk warning

As mentioned above, the estimated results set out above are only a preliminary assessment by the finance department of the Company and have not been audited by any accounting firm. As at the date of this announcement, there are no material uncertainties affecting the accuracy of the contents of the estimated results.

5. Other matters

The estimated results set out above are only preliminary accounting data, and the actual results of the Company for 1H2023 shall be subject to the interim results announcement of the Company for 1H2023 to be released by the Company in due course.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 July 2023